Credit Suisse Sees Interest Growing in Anti-CD47 Therapies, Reiterates Outperform Rating on ALX Oncology (ALXO)
Tweet Send to a Friend
Credit Suisse analyst Tiago Fauth reiterated an Outperform rating and $100.00 price target on ALX Oncology (NASDAQ: ALXO) after Pfizer ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
